Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17630232 | 0.92 | TBK1 (0.44) | TBK1IKBKE | |
| SCHEMBL17630235 | 0.92 | TBK1 (0.44) | TBK1IKBKE | |
| SCHEMBL15716135 | 0.86 | XDH (0.44) | TBK1IKBKE | |
| SCHEMBL24860958 | 0.86 | XDH (0.47) | TBK1IKBKE | |
| SCHEMBL14977113 | 0.85 | TBK1 (0.40) | TBK1IKBKE | |
| SCHEMBL17306341 | 0.85 | XDH (0.46) | TBK1IKBKE | |
| SCHEMBL17630225 | 0.84 | TBK1 (0.56) | TBK1IKBKE | |
| SCHEMBL17289929 | 0.83 | TBK1 (0.46) | TBK1IKBKE | |
| SCHEMBL17289661 | 0.82 | TBK1 (0.38) | TBK1IKBKE | |
| SCHEMBL22470817 | 0.82 | TBK1 (0.51) | TBK1IKBKE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3517536-B1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | MERCK PATENT GMBH (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-3517536-A1 | AMINOTRIAZINE DERIVATIVES USEFUL AS TANK-BINDING KINASE INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-07-31 | — | — | EP | disclosed |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2019-01-17 | — | — | US | disclosed |
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. | 2018-12-27 | — | — | US | disclosed |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2018-09-11 | — | — | US | disclosed |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-08-30 | — | — | US | disclosed |
| EP-1992361-B1 | Remedy or preventive for digestive ulcer | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8067446-B2 | Methods for treating an ulcer of the small intestine and stomach | ASTELLAS PHARMA INC. (JP) | 2011-11-29 | — | — | US | disclosed |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| WO-2011046970-A1 | AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBKL AND/OR IKK EPSILON | MYREXIS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| US-7820700-B2 | 2-phenylpyridine derivative | ASTELLAS PHARMA INC. (JP) | 2010-10-26 | — | — | US | disclosed |
| EP-1783116-B1 | 2-PHENYLPYRIDINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2009-08-26 | — | — | EP | disclosed |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | ASTELLAS PHARMA INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1992361-A1 | REMEDY OR PREVENTIVE FOR DIGESTIVE ULCER | Astellas Pharma Inc. (JP) | 2008-11-19 | — | — | EP | disclosed |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1783116-A1 | 2-PHENYLPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180370955-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885IKBKE 41/4885 |
| US-20070275950-A1 | 2-Phenylpyridine Derivative | NLRP3, XDH, UACA | TBK1 926/4885IKBKE 328/4885 |
| US-10428080-B2 | TBK/IKK inhibitor compounds and uses thereof | NFKBIA, TBKBP1, TBK1 | TBK1 3/4885IKBKE 4/4885 |
| US-10259811-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885IKBKE 41/4885 |
| US-20090036428-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | TBK1 1733/4885IKBKE 1415/4885 |
| US-10253019-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885IKBKE 41/4885 |
| US-10072001-B2 | Tank-binding kinase inhibitor compounds | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885IKBKE 41/4885 |
| US-20190016717-A1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | TBKBP1, TNKS1BP1, TNKS | TBK1 4/4885IKBKE 41/4885 |
| US-20180244682-A1 | TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | NFKBIA, TBKBP1, TBK1 | TBK1 3/4885IKBKE 4/4885 |
| US-20110281919-A1 | AGENT FOR TREATING OR PREVENTING DIGESTIVE ULCER | XDH, PEPD, HPN | TBK1 1733/4885IKBKE 1415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.